Why Is SOTERA HEALTH CO (SHC) Stock Down Today?

Sotera Health Co (SHC) shares fell 9.64% to $16.03 on Monday. The decline followed the company’s third-quarter 2026 earnings release, which included reaffirmed full-year guidance but a slight reduction in sales targets. Investors focused on the impact of European medical device softness and foreign exchange risks on the company’s outlook.

What Happened

Sotera Health reported third-quarter 2026 results that exceeded expectations for both revenue and earnings per share. Adjusted EPS came in at $0.29, surpassing the $0.27 estimate, while sales of $324.886 million beat the $319.774 million forecast. Despite the strong top-line performance, the company lowered its full-year 2026 sales guidance from a range of $1.236 billion to $1.254 billion to a new range of $1.233 billion to $1.250 billion. The adjusted EPS guidance for fiscal year 2026 was reaffirmed at $0.95 to $1.01. Management cited European medical device softness and foreign exchange headwinds as primary factors shaping the quarter’s outlook. The company also noted progress on its commercial-scale Cobalt-60 production initiative. A Form 8-K filed with the SEC on November 3, 2026, disclosed the results of operations and financial condition.

What The Data Shows

The stock’s market capitalization stands at $5.2 billion with a P/E ratio of 31.3. Trailing twelve-month revenue grew 8.1%, and the net margin is 13.4%. The stock has a beta of 1.86 and a 52-week range of $13.09 to $19.85. Over the last eight sessions prior to the drop, the stock moved down 2.5% from $18.35 to $17.90. On November 3, 2026, the stock printed two fresh 52-week highs and 25 fresh 52-week lows. Recent insider activity includes two sales totaling $24.0 million over the last 90 days, with no buys recorded. The most recent insider sale was executed on August 19, 2026.

What To Watch

Investors will monitor the company’s ability to navigate European market conditions and foreign exchange volatility in the coming quarters. The reaffirmed adjusted EPS guidance of $0.95 to $1.01 for fiscal year 2026 remains a key metric for assessing future performance.